Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

118 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
The incidence and risk factors of febrile neutropenia in chemotherapy-naïve lung cancer patients receiving etoposide plus platinum.
Fujiwara T, Kenmotsu H, Naito T, Kawamura T, Mamesaya N, Kotake M, Kobayashi H, Omori S, Nakashima K, Wakuda K, Ono A, Taira T, Murakami H, Omae K, Mori K, Endo M, Takahashi T. Fujiwara T, et al. Among authors: kotake m. Cancer Chemother Pharmacol. 2017 Jun;79(6):1229-1237. doi: 10.1007/s00280-017-3324-7. Epub 2017 Apr 28. Cancer Chemother Pharmacol. 2017. PMID: 28455585
Efficacy of prophylactic cranial irradiation in patients with limited-disease small-cell lung cancer who were confirmed to have no brain metastasis via magnetic resonance imaging after initial chemoradiotherapy.
Mamesaya N, Wakuda K, Omae K, Miyawaki E, Kotake M, Fujiwara T, Kawamura T, Kobayashi H, Nakashima K, Omori S, Ono A, Kenmotsu H, Naito T, Murakami H, Mori K, Harada H, Endo M, Nakajima T, Takahashi T. Mamesaya N, et al. Among authors: kotake m. Oncotarget. 2018 Apr 3;9(25):17664-17674. doi: 10.18632/oncotarget.24830. eCollection 2018 Apr 3. Oncotarget. 2018. PMID: 29707139 Free PMC article.
Efficacy and safety of immune checkpoint inhibitor monotherapy in pretreated elderly patients with non-small cell lung cancer.
Yamaguchi O, Imai H, Minemura H, Suzuki K, Wasamoto S, Umeda Y, Osaki T, Kasahara N, Uchino J, Sugiyama T, Ishihara S, Ishii H, Naruse I, Mori K, Kotake M, Kanazawa K, Minato K, Kagamu H, Kaira K. Yamaguchi O, et al. Among authors: kotake m. Cancer Chemother Pharmacol. 2020 Apr;85(4):761-771. doi: 10.1007/s00280-020-04055-7. Epub 2020 Mar 19. Cancer Chemother Pharmacol. 2020. PMID: 32193618
Phase I study of nab-paclitaxel plus carboplatin and concurrent thoracic radiotherapy in patients with locally advanced non-small cell lung cancer.
Kaira K, Tomizawa Y, Imai H, Sakurai R, Matsuura M, Yoshii A, Ochiai M, Kotake M, Ebara T, Saitoh JI, Sunaga N, Minato K, Saito R, Hisada T. Kaira K, et al. Among authors: kotake m. Cancer Chemother Pharmacol. 2017 Jan;79(1):165-171. doi: 10.1007/s00280-016-3217-1. Epub 2016 Dec 19. Cancer Chemother Pharmacol. 2017. PMID: 27995307 Clinical Trial.
Post-progression survival is highly linked to overall survival in patients with non-small-cell lung cancer harboring sensitive EGFR mutations treated with first-line epidermal growth factor receptor-tyrosine kinase inhibitors.
Imai H, Kaira K, Mori K, Kotake M, Mitani M, Kawashima N, Hisada T, Minato K. Imai H, et al. Among authors: kotake m. Thorac Cancer. 2019 Dec;10(12):2200-2208. doi: 10.1111/1759-7714.13193. Epub 2019 Oct 8. Thorac Cancer. 2019. PMID: 31595714 Free PMC article.
Efficacy and safety of first-line pembrolizumab monotherapy in elderly patients (aged ≥ 75 years) with non-small cell lung cancer.
Imai H, Wasamoto S, Yamaguchi O, Suzuki K, Sugiyama T, Uchino J, Minemura H, Osaki T, Ishii H, Umeda Y, Mori K, Kotake M, Kagamu H, Morozumi N, Taniguchi H, Kasai T, Minato K, Kaira K. Imai H, et al. Among authors: kotake m. J Cancer Res Clin Oncol. 2020 Feb;146(2):457-466. doi: 10.1007/s00432-019-03072-1. Epub 2019 Dec 18. J Cancer Res Clin Oncol. 2020. PMID: 31853661
118 results